QC
COYA icon

Quadrature Capital’s Coya Therapeutics COYA Stock Holding History

Quadrature Capital’s Portfolio COYA Stock Details COYA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-19,894
Closed -$114K – 1321
2025
Q3 		$114K Buy
+19,894
New +$121K ﹤0.01% 862

Other funds holding COYA

DCM
DME Capital Management New York $3.19B AUM 23.22% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
AIC
AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return
CM
CM Management Gulf Breeze, Florida $120M AUM 37.12% 1-Year Est. Return
PMG
Private Management Group Irvine, California $3.8B AUM 23.19% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Quadrature Capital's COYA Position: Q4 2025 in Review

Quadrature Capital sold out of Coya Therapeutics (COYA) in Q4 2025, closing a stake of 19,894 shares — an estimated $114K sold.

Quadrature Capital first reported a position in COYA in Q3 2025 and held it in 1 quarter. The position peaked at $114K in Q3 2025. 58 funds tracked by Wall St. Rank hold COYA as of Q4 2025.

  • Quadrature Capital reported no remaining Coya Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Quadrature Capital sold 19,894 Coya Therapeutics shares in Q4 2025, an estimated $114K.
  • Quadrature Capital first reported a position in Coya Therapeutics in Q3 2025 and held it in 1 quarter.
  • Quadrature Capital's Coya Therapeutics position peaked at $114K in Q3 2025.
  • 58 funds tracked by Wall St. Rank held Coya Therapeutics as of Q4 2025.

Based on Quadrature Capital's 13F filing for Q4 2025, filed 17 Feb 2026.